

## LightOn Announces Successful IPO on Euronext Growth Paris

Paris, November 27, 2024

LightOn, a European leader in generative AI solutions for businesses, proudly announces the successful completion of its IPO on Euronext Growth Paris. The offering raised €11.9 million, with potential to reach €13.5 million upon full exercise of the over-allotment option. With strong investor demand totaling €15.2 million—1.5 times oversubscribed—the company now has a market capitalization of approximately €62 million.

The funds will accelerate LightOn's growth, enabling team expansion and enhanced R&D for its flagship generative AI platform, Paradigm. Trading begins on November 26, 2024, under the ticker ALTAI-FR.

We at Quantonation are thrilled to celebrate this monumental milestone with the LightOn team. Their journey from an ambitious startup to becoming a publicly traded company is a testament to their work on photonic chips and visionary development of Generative Al applications since 2020. As early backers of LightOn, we are proud to have been part of their journey and look forward to seeing their continued growth and impact. Congratulations to Laurent Daudet and Igor Carron, and the entire team for their remarkable achievement.

Co-founders and CEOs Igor Carron and Laurent Daudet expressed gratitude to new shareholders, stating, "This milestone will help us drive innovation and transform business applications through generative AI."

## About lightOn:

Founded in 2016, LightOn is a European pioneer in generative AI solutions for businesses. Leveraging innovative photonic chip technology and cutting-edge AI research, LightOn develops tools like the Paradigm platform to transform enterprise operations across industries. Headquartered in Paris, the company is at the forefront of advancing AI-driven innovation on a global scale.

## **About Quantonation:**

Quantonation is the first early-stage VC fund dedicated to deep physics and quantum technologies. Field such as high-performance computation, secure communications, drug design or ultra-precise sensing are now driven by innovation based on these disruptive technologies. Quantonation aims at supporting their transition into commercially available products. Quantonation is headquartered in Paris, France, and in Boston, USA, with investments in Europe, North America, and Asia-Pacific.

Contact from Quantonation: <u>Eleonore@quantonation.com</u>
For more information on the operation, please consult official press release here: <u>LightOn</u> announces highly successful IPO